CD BioGlyco Announced Service for Analysis of Glycolytic Enzymes in Cancer Cells
CD BioGlyco, a biotechnology company that provides multi-omics analysis of cancer cell glycolysis including genomics, proteomics, metabolomics and metabolic fluxomics, now offers analysis of glycolytic enzymes in cancer cells, enabling thorough understanding of cancer cell glycolysis pathways.
The capacity of cancer cells for aerobic glycolysis is 20–30 times greater than that of normal cells, and the enhancement of glycolysis encourages the malignant development of cancer. Increasing the activity of glycolytic enzymes and overexpressing them are the primary methods for enhancing glycolysis in cancer cells. As a result, the expression, activity, and interactions of enzymes at various points along the glycolytic pathway are primarily examined in proteomic analysis of cancer cell glycolysis. Antitumor therapy now focuses on targeting enzymes that are abnormally expressed in cancer cells.
Three irreversible and numerous reversible enzymatic reactions can occur along the glycolytic pathway. The metabolic reprogramming of cancer involves modifications in the glycolytic pathway's enzymatic response in cancer cells.
Based on proteomics technology, CD BioGlyco offers quantitative analysis of the enzymes in each step of the glycolytic pathway, analysis of post-translational modifications, and analysis of interactions. CD BioGlyco can offer services for quantification, modification analysis, and related protein interaction analysis for enzymes including: Hexokinase, Phosphate isomerase, Phosphofructokinase, Aldolase, Triose-phosphateisomerase, Glyceraldehyde 3-phosphate dehydrogenase, Phosphoglycerate kinase, Phosphoglycerate mutase, Enolase, and Pyruvate kinase.
Based on the information of CD BioGlyco’s official website, its services can be applied to investigate the relationship between signaling pathways and enzyme expression and find targets for cancer metabolism regulation, and to study the regulation of transcription factors on the glycolytic pathway in cancer.
Customers can get assistance from CD BioGlyco in analyzing post-translational modifications, interactions with other proteins, and the quantitative expression of every enzyme involved in the glycolytic pathway.
CD BioGlyco also provides analysis of glycolysis related genes, detection of glycolytic metabolites in cancer cells, and analysis of glycolytic metabolic flux in cancer cells for cancer cell glycolytic analysis service.
Please visit https://www.bioglyco.com/analysis-of-glycolytic-enzymes-in-cancer-cells.html to know more about the Analysis of Glycolytic Enzymes in Cancer Cells newly launched by CD BioGlyco.